

Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

NCT07508306

Status	RECRUITING
Sponsor	Faculty of Medicine of Tunis
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Age : aged 18 years-old or older
- Diagnosis: Suspected Ovarian cancer on MRI finding (O-RADs 4 or 5)
- FIGO stage: Stage I or II (Based on MRI and scanner finding)
- Planned Procedure: Patients with planned for surgical complete stadification including pelvic and para-aortic lymphadenectomy
- Consent: Signing of the written informed consent after full information has been provided

Exclusion (5)

- Suspicious nodal involvement: Presence of suspicious lymph nodes on preoperative imaging (generally defined by a short-axis diameter e 10 mm).
- Disease extension: Radiological or intraoperative evidence of extra-pelvic metastases or peritoneal carcinomatosis.
- Surgical history: History of lymphadenectomy, lymph node sampling, or major vascular surgery involving the aorta or the iliac vessels.
- History of radiotherapy: Patients who have previously undergone pelvic or abdominal radiotherapy.
- Allergies: Known allergy or adverse reaction to patent blue dyes.

Locations (1 total)

Maternity and neonatology center of Tunis, La Rabta, Tunisia